

References

- Abiziad AS, Clark CE, Mintz GS, Dosa S, popma JJ, Pichard AD, Satjer LF, Harvy M, Kent KM, and Leoin MB. (1999):** Effects of dopamine and aminophylline on contrast-induced nephropathy after coronary angiography in patients with pre-existing renal insufficiency. *Am J Cardiol*; 83:260-263.
- Aleksa K, Matsell D, Krausz K, Gelboin H, Ito S, Koren G. (2005):** Cytochrome P450 and 2B6 in the developing kidney: Implications for ifosfamide nephrotoxicity. *Pediatr Nephrol*; 20: 872–885.
- Almen T, Frennby B, Sterner G, et al. (1999):** Determination of glomular filtration rate (GFR) with contrast media. *Trends in contrast media*. Berlin:Springer Verlag; 81:1742.
- Alves-Rodrigues EN, Ribeiro LC, Silva MD, Takiuchi A, Fontes CJ. (2005):** Dapsone syndrome with acute renal failure during leprosy treatment: case report. *Braz J Infect Dis*; 9(1):84-86.
- Agrawal M, Stouffer GA, et al. (2002):** Contrast induced nephropathy after angiography. *Am J Med Sci*; 323:252-258.
- Anders HJ, Banas B, Schlondorff D, Signaling danger. (2004):** toll-like receptors and their potential roles in kidney disease. *J Am Soc Nephrol*; 15: 854-867.
- Andrade L, Campos SB, Seguro AC, et al. (1998):** Hypercholesterolemia aggravates radiotoxic nephrotoxicity. Protective role of L-arginine. *Kidney Int*; 53:1736-1742.
- Andreucci M, Michael A, Kramers C, Park KM, Chen A, Matthaeus T, Alessandrini A, Haq S, Force T, Bonventre JV. (2003):** Renal ischemia/reperfusion and ATP depletion/repletion in LLC-PK(1) cells result in phosphorylation of FKHR and FKHL1. *Kidney Int*; 64:1189-1192.

- Apoor S, Gami R, Vensa D, Garovic JK. (2004):** Contrast Nephropathy After Coronary Angiography . Division of Cardiovascular Diseases and Internal medicine (A.S.G), Mayo Clinic College of Medicine; 13:314-321.
- Appel GB. (2005):** Acute interstitial nephritis. In Immunologic Renal Disease (**ed. Couser WG and Neilson EG**) PA: Lippincott Williams and Williams; 45:1269-1281.
- Arakawa K, Suzuki H, Naitho M. (1996):** Role of adenosine in the renal responses to contrast medium. *Kidney Int*; 49:1199-1206.
- Arany I, Judit K, Megyesi JK, Kaneto H, Price PM, Safirstein RL. (2004):** Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. *Am J Physiol Renal Physiol*; F287-F543.
- Arije A, Kadiri S, Akinkugbe OO, et al. (2000):** The viability of hemodialysis as a treatment option for renal failure in a developing economy. *Afr J Med Med Sci*; 29: 311–314.
- Arribas-Gomez I, Duque-Marin I, Perez LG, Diez-Marques ML, Lucio-Cazana J, Rodriguez-Puyol M, Rodriguez-Puyol D. (1995):** A possible role for platelet-activating factor in the hydrogen peroxide-induced TXB2 and PGE2 glomerular synthesis. *J Lipid Res*; 36: 260–265.
- Asbel LE, Levison ME, et al. (2000):** Cephalosporins, carbapenems, and monobactams. *Infect Dis Clin North Am*; 14(2): 435-437.
- Ashby DT, Mehran R, Aymong EA. (2003):** Comparison of outcomes in men versus women having percutaneous coronary interventions in small coronary arteries. *Am. J. Cardiol*; 91:979-981.
- Askenazi DJ, Feig DI, Graham NM, Hui-Stickle S, Goldstein SL. (2006):** 3–5 year longitudinal follow-up of pediatric patients after acute renal failure. *Kidney Int*; 69: 184–189.
- Azmus AD, Gottschall C, Manica A, et al. (2005):** Effectiveness of acetylcysteine in prevention of contrast nephropathy. *J Invasive Cardiol*; 17:80-84.

- Baciewicz AM, Sokos DR, Cowan RI. (2003):** Aminoglycoside-associated nephrotoxicity in the elderly. *Ann Pharmacother*; 37: 182-186.
- Bader BD, Bosker J, Risler T, Erley CM. (2001):** Contrast media-induced kidney failure cannot be prevented by hemodialysis. *Dutch Med Nephrol*; 126: 162-166.
- Bader BD, Berger ED, Heede MB. (2004):** what is the best hydration regimen to prevent contrast media-induced nephrotoxicity?. *Clin Nephrol*; 62:1-7.
- Bailey TC, Little JR, Littenberg B, Reichhley RM, Dunagan WC. (1997):** A meta- analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. *Clin Infect Dis*; 24: 786-95.
- Barclay ML, Kirkpatrick CM, Begg EL. (1999):** Once daily aminoglycoside therapy. Is it less toxic than multiple doses and how should it be monitored? *Clin Pharmacokinet*; 36:89.
- Bartal C, Danon A, Schlaffer F, Reisenberg K, Alkan M, Smoliakov R, Sidi A, Almog Y. (2003):** Pharmacokinetic dosing of aminoglycosides: a controlled trial, *Am J Med*; 114: 194-98.
- Bartholomew BA, Harjai KJ, Dukkupati S. (2004):** Impact of nephropathy after percutaneous coronary intervention and a method for risk satisfaction. *Am J Cardiol*; 93:1515-1519.
- Bellinger DC, Trachtenberg F. (2006):** "Neuropsychological and renal effects of dental amalgam in children: a randomized clinical trial." *JAMA*; 295(15): 1775-1783.
- Bennett WM, Elliott WC, Houghton DC, Gilbert DN, DeFehr J, McCarron DA. (1982):** Reduction of experimental gentamicin nephrotoxicity in rats by dietary calcium loading, *Antimicrob Agents Chemotherap*; 22(3): 508-12.
- Berns JS, Kasbekar N, et al. (2006):** Highly active antiretroviral therapy and the kidney: An update on antiretroviral medications for nephrologists. *Clin J Am Soc Nephrol*;1:117-129.

- Bertino JS, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. (1993):** Incidence of and significant risk factors for aminoglycoside associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. *J Inf Dis*; 167:173-79.
- Bertram GK (2007):** General Properties of Aminoglycosides. "Basic & Clinical Pharmacology "; 45(10): 478 479.
- Bigazzi PE, et al. (1999):** Metals and kidney autoimmunity. *Environmental Health Perspectives*; 107:753-765.
- Bledsoe G, Shen B, Yao YY, et al. (2008):** Role of tissue Kallikrein in prevention and recovery of gentamicin-induced renal injury. *Toxicol Sci*; 102(2):433-443.
- Bode U, Seif SM, Levin AS. (2002):** Studies on the antidiuretic effect of cyclophosphamide: vasopressin release and sodium excretion. *Med Pediatr Oncol*; 8:295-303.
- Brady HR, Kone BC, Stroniski ME, Zeidel ML, Giebisch G, Gullans SR. (2004):** Mitochondrial injury: an early event in cisplatin-toxicity to renal proximal tubules. *Am J Physiol*; 258: F1181-7.
- Brater DC, Brater DC, et al. (2002):** Anti-inflammatory agents and renal function. *Seminars in Arthritis & Rheumatism*; 32: 33-42.
- Brewster UC, Perazella MA, et al. (2002):** Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. *Am J Kidney Dis*; 40:1331-3.
- Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ. (1996):** Acute renal failure in intensive care units--causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. *Crit Care Med*; 24:192-198.
- Bucarechi F, Vicente DC, Pereira RM, Tresoldi AT. (2004):** Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy. *Revista do Instituto de Medicina Tropical de Sao Paulo*; 46(6): 331-4.

- Buchler M, Leibenguth P, Le Guellec C, Carayon A, Watier H, Odoul F, Autret-Lec, E, Lebranchu Y Paintaud G. (2004):** Relationship between calcineurin inhibition and plasma endothelin concentrations in cyclosporine-A-treated kidney transplant patients. *Eur J Clin Pharmacol*; 60:703-708.
- Burckhardt G, Wolff NA. (2000):** Structure of renal organic anion and cation transporters. *Am J Physiol Renal Physiol*; 278:F853.
- Carraro M, Mancini W, Artero M, Stacul F, Grotto M, Cova M, Faccini L. (1996):** Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. *Nephrol Dial Transplant*; 11: 444-448.
- Chambers HF. (2006):** Chapter 43, Beta-lactam and other cell wall and membrane-active antibiotics, In *Basic and clinical pharmacology*, 10th edition, editors Katzung B, McGraw-Hill Medical, New York.
- Chew ST, Newman MF, White WD, Conlon PJ, Saunders AM, Strittmatter WJ, Landolfo K, Grocott HP, Stafford-Smith M. (2000):** Preliminary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients. *Anesthesiology*; 93:325-331.
- Chia KS, Mutti A, Tan C. (1994):** Urinary N-acetyl-beta-Dglucosaminidase activity in workers exposed to inorganic lead. *Occup Environ Med*; 51(2): 125-129.
- Chow YW, Lim BB, Hooi LS. (2007):** Acute Renal Failure in the Same Hospital Ten Years Apart. *Med J Malaysia*; 62:28-30.
- Chua BT, Guo K, Li P, et al. (2000):** Direct cleavage by the calcium-activated protease calpain can lead to inactivation of caspases. *J Biol Chem*; 275:5131.
- Coco TJ, Klasner AE. (2004):** Drug-induced rhabdomyolysis. *Curr Opin Pediat*; 16: 206-210.
- Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, Vera M, Piera C, Darnell A. (2000):** Serum cystatin C as a new marker for noninvasive

estimation of glomerular filtration rate and as a marker for early renal impairment. *Am J Kidney Dis*; 36: 29-34.

Conesa El, Valero F, Nadal JC, Fenoy FJ, Lopez B, Arregui B, Salom MG. (2001): N-acetyl-L-cystiene improves renal medullary hypoperfusion in acute renal failure. *American Journal of Physiology. Regulatory Integrative, and Comparative physiology*; 281:R730-R737.

Cooke MS, Evans MD, Dizdaroglu M, Lunce J. (2003): Oxidative DNA damage: Mechanisms, mutation, and disease. *FASEB J*; 17:1195-1214.

Cummings BS, Schnellmann RG, et al. (2002): Cisplatin-induced renal cell apoptosis: caspase 3 dependent and independent pathways. *J Pharmacol Exp Ther.* 2002;302:172-173.

Cummings BS, McHowat J, Schnellmann RG. (2004): Role of an endoplasmic reticulum Ca²⁺-independent phospholipase A2 in cisplatin-induced renal cell apoptosis. *J Pharmacol Exp Ther*; 308:921.

Cuzzocrea S, Mazzon E, Dugo L. (2002): A role for superoxide in gentamicin-mediated nephropathy in rats. *Eur J Pharmacol*; 450:67-76.

Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DF. (2003) : cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity, *Pharmacother*; 23(5): 643-50 197.

Demczar DJ, Nafziger AN, Bertino Jr, et al. (1997): Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. *Antimicrob. Agents Chemother*; 41:1115–1119.

Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. (2002): Acetylcysteine to prevent angiography-related renal tissue injury (The APART Trial). *Am J Cardiol*; 89:356-358.

Dishart M, Kellum JA. (2000): An evaluation of pharmacological strategies fro the prevention and treatment of acute renal failure. *Drugs* 2000; 59: 79-91.

- Diott JS, Danielson CF, Blue-Hnidv DE, McCarthy LJ. (2004):** Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review. *Ther Apher Dial*; 8:102-111.
- Donovan N, Becker EB, Konishi Y, Bonni A. (2002):** JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery. *J Biol Chem*; 277: 4944–4949.
- Dooley JS, James CA, Rogers HJ, Stuart-Harris GJ. (2005):** Biliary elimination of cyclophosphamide in man. *Cancer Chemother Pharmacol*;9:26-29.
- Ekert PG, Silke J, Vaux DL. (1999):** Inhibition of apoptosis and clonogenic survival of cells expressing crmA variants: optimal caspase substrates are not necessarily optimal inhibitors. *Embo J*; 18:330.
- El-Mouedden M, Laurent G, Mingeot-Leclercq MP, Taper HS, Cumps J, Tulkens PM. (2000):** Apoptosis in renal proximal tubules of rats treated with low doses of aminoglycosides. *Antimicrob Agents Chemotherap*; 44(3): 665-675.
- Elting LS, Rubenstein EB, Kurtin D, Rolston KV, Fangtang J, Martin CG, Raad II, Whimbley EE, Manzullo E, Bodey GP. (1998):** risks and outcomes of vancomycin-associated toxicity in general oncology practice, *Cancer*; 83: 2597-607.
- Erley CM, Duda SH, Schlepckow S, Koehler J, Huppert PE, Strohmaier WL, Bohle A, Risler T, Osswald H. (1994):** Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. *Kidney Int*; 45:1425-1431.
- Erley CM, Duda SH, Rehfuse D, Scholets B, Bock J, Muller C, Osswald H. (1999):** Prevention of radiocontrast media induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with adenosine antagonist theophylline. *Nephrol Dial Transplant*; 14:1146-1149.

- Ergun I, Kenan K, Uruc I, Ekmekci Y, Canbakan B, Erden I, Karatan O. (2006):** The safety of gadolinium in patients with stage 3 and 4 renal failure. *Nephrol Dial Transplant*; 21: 697–700.
- Esnault VL (2002):** Radiocontrast media-induced nephrotoxicity in patients with renal failure: rationale for a new double-blind, prospective, randomized trial testing calcium channel antagonist. *Nephrol Dial Transplant*; 17:1362-1364.
- Evans JMM, McGregor E, McMahon AD, McGilchrist MM, Jones MC, White G, McDevitt DG, MacDonald TM. (1995):** Non-steroidal drugs anti-inflammatory drugs and hospitalization for acute renal failure. *Q J Med*; 88: 551-557.
- Fabris B, Bortoletto M, Candido R, Barbone F, Cattin MR, Calci M, Scanferla F, Tizzoni L, Giacca M, Carretta R. (2005):** Genetic polymorphisms of the rennin-angiotensin-aldosterone system and renal insufficiency in essential hypertension. *J Hyperten*; 23:309-316
- Fiaccadori E, Durham JM, Marizo K, Rundnick M. (2004):** N-Acetylcysteine in the prevention of radiocontrast media-induced nephropathy. *J Am Soc Nephrol*; 15:251-260.
- Fishbane S, Durham JH, Rudnick M. (2004):** N-acetylcysteine in the prevention of Contrast media-induced nephropathy. *Journal of American Society of Nephrology*; 15:251-260.
- Fored CM, Ejlerblad E, Lindblad P, et al. (2006):** Acetaminophen, aspirin, and chronic renal failure.. *New England Journal of Medicine*;345: 1801-1808.
- Franchini I, Alinovi R, Bergamaschi E, Mutti A. (2005):** Contribution of studies on renal effects of heavy metals and selected organic compounds to our understanding of the progression of chronic nephropathies towards renal failure. *ACTA BIOMED*; 2: 58-67.
- Frank H, et al. (2003):** Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. *Clin Nephrol*; 60:176.

- Friedewald JJ, Rabb H. (2004):** Inflammatory cells in ischemic acute renal failure. *Kidney Int*; 66:486.
- Fried L, Solomon C, Shlipak M, Seliger S, Stehman-Breen C, Bleyer AJ, Chaves P, Furberg C, Kuller L, Newman A. (2004):** Inflammatory and prothrombic markers and the progression of renal disease in elderly individuals. *J Am Soc Nephrol*; 15:3184-3191.
- Gauffre A, Mircheva J, Glotz D, Fillastre JP, Simon P, Beaune PH. (2001):** Autoantibodies against a kidney--liver protein associated with quinolone-induced acute interstitial nephritis or hepatitis. *Nephrol Dial Transplant*; 12(9):1961-2.
- Gilbert DN, et al. (1998):** A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate. *Am J Med*; 105:256.
- Girmenia C, Cimino G, Micozzi A, et al. (2002):** Risk Factors For Nephrotoxicity Associated With Conventional Amphotericin B Therapy. *The American Journal of Medicine*; 113:351.
- Glauser J, Queen JR. (2007):** An overview of non-cardiac cocaine toxicity. *J Emer Med*; 32:181-186.
- Gopee NV, He Q, Sharma RP. (2003):** Fumonisin B1-induced apoptosis is associated with delayed inhibition of protein kinase C, nuclear factor-kappaB and tumor necrosis factor alpha in LLC-PK1 cells. *Chem Biol Interact*; 146:131.
- Graham, DJ, Judy A, Susan E, Stephane D, Jerry H, Michel J. (2004):** Incidence of hospitalized in patients treated with lipid-lowering drugs. *JAMA*; 292:2585.
- Grant B, Sarah C, Jenny M, Chun-Fang X, Hideyuki M, Lee C, Julie C. (2006):** Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. *Nephrol Dial Transplant*; 21: 624-633.

- Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, Pichard AD, Satler LF, Leon MB. (2000):** The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existing chronic renal insufficiency. *J Am Coll Cardiol*; 36:1542-1548.
- Gruberg L, Mehran R, Dangas G, Mintz GS, Waksman R, Kent KM, Pichard AD, Satler LF , Wu H, Leon MB. (2005):** Acute renal failure requiring dialysis after percutaneous coronary interventions. *Catheter Cardiovasc Interv*; 52: 409-416.
- Goldnberg I, Matetzky S, et al. (2005):** Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. *Canadian Medical Association Journal*; 172:1461-1471.
- Guitard J, Kamar N, Mouzin M, Borde JS, Tran-Van T, Durand D. 2005:** Sulfadiazine-related obstructive urinary tract lithiasis: an unusual cause of acute renal failure after kidney transplantation. *Clinical nephrology*; 63(5):405-407.
- Gumprecht J, Zychma J, Grzeszczak W, Zukowska-Szczechowska E. (2000):** A study group. Angiotension I converting enzyme gene insertion/deletion and angiotensionogen M235T polymorphism. *Kidney Int*; 58: 513-519.
- Haas SJ, Aw TJ, Liew D, Krum H. (2005):** Meta-analysis of Cyclooxygenase -2 inhibitors and their effects on blood pressure. *Arch Intern Med*; 165:490-496.
- Hanabusa H, Tagami H, Hataya H. (1999):** Renal atrophy associated with long term treatment with pentamidine. *New Engl J Med*; 340:392-393.
- Hans SS, Hans BA, Dhillon R, Dmuchowski C, and Glover J. (1998):** Effect of dopamine on renal function after angiography in patients with pre-existing renal insufficiency. *Am Surg*; 64:432-436.

- Harada D, Naito S, Hiraoka I, Otagiri M. (2002):** In vivo kinetic analysis of covalent binding between N-acetyl-L-cysteine and plasma protein through the formation of mixed disulfide in rats. *Nephrol Dial Transpl*; 19:615-620.
- Harbarth S, Pestotnik SL, Lloyd JF, et al. (2001):** The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. *Am J Med*;111:528-34.
- Hendriks JGE, van Horn JR, van der Mei HC, Busscher HJ. (2004):** Backgrounds of antibiotic loaded bone cement and prosthesis-related infection. *Biomaterials*; 25:545–556.
- Henrich WL (2005):** Nephrotoxicity of several new agents. *Kidney International*; 67: 107-109.
- Heyman SN, Goldfard M, Shian A, Karmeli F, Rosen S. (2003):** N-acetyl-L-cystiene ameliorates renal microcirculation: Studies in rats. *Kidney Int*; 63: 634-642.
- Heyman SN, Rosenberger C, Rosen S. (2005):** regional alterations in renal hemodynamics and oxygenation: a role in contrast medium induced nephropathy. *Nephrol Dial Transpl*; 20: 6-11.
- Higuchi M, Agatsuma T, Iizima M, Yamazaki Y, Saita T, Ichikawa T. (2005):** A case of drug-induced hypersensitivity syndrome with multiple organ involvement treated with plasma exchange. *Ther Apher Dial*; 9(5):412-6.
- Hitt CM, Klepser ME, Nightingale CH, Quintiliani R, Nicolau DP. (2007):** Pharmacoeconomic impact of once-daily aminoglycoside administration. *Pharmacotherapy*; 17(4): 810-814.
- Hodgson S, Nieuwenhuijsen MJ. (2007):** “Kidney disease mortality and environmental exposure to mercury.” *Am J Epidemiol*; 165(1): 72-77.
- Hong SH, Park SK, Cho YS, Lee HS, Kim KR, Kim MG, Chung WH. (2006):** Gentamicin induced nitric oxide-related oxidative damages on vestibular afferents in the guinea pig. *Hear. Res*; 211:46–53.

- Hooper D, Mandel GL, Dolin R. (1995):** Principles and practice of infectious diseases. New York: Churchill Livingstone; 364-76.
- Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum J. (2006):** RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. *Crit Care*; 10:R73-78.
- Hsu SC, TerBush D, Abraham M. (2004):** The exocyst complex in polarized exocytosis. *Int Rev Cytol*; 233:243–65.
- Hsu SC, Lai TL, Lien WC, Chen WJ, Fang CC. (2005):** Emergent hemodialysis for acyclovir toxicity. *Am J Emerg Med*; 23(7); 899-900.
- Huerta-Alarden AL, Varon J, Marik PE. (2005):** Bench-to-bedside review: rhabdomyolysis overview for clinicians. *Crit Care*; 9:158-169.
- Huerta C, Castellsague J, Varas-Lorenzo C, Gracia Rodriguez LA. (2005):** Nonsteroidal anti-inflammatory drugs and risk of AFR in the general population. *American Journal of Kidney Disease*; 45:531-539
- Hutchinson FN, Perez EA, Gandara DR, Lawrence HJ, Kaysen G. (2003):** Renal salt-wasting in patients treated with cisplatin. *Ann Intern Med*; 108:21-5.
- International Program on Chemical Safety- the United Nations Environment Program, the International Labor Organization, and the World Health Organization (IPCS-UNEP-ILO-WHO).** Principles and methods for the assessment of nephrotoxicity associated with exposure to chemicals. Environmental Health Criteria series, n. 119, World Health Organization, Geneva, 1991.
- Itkin YM and Trujillo TC, et al. (2005):** Intravenous immunoglobulin-associated acute renal failure: case series and literature review. *Pharmacotherapy*; 25:886-892.

- Itizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. (1999):** Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. *Kidney Int*; 55: 1945-1951.
- Iyisoy A, Celik T, Yuksel UC, Bugan B, Isik E. (2009):** The value of hydration and acetylcysteine in the prevention of contrast induced nephropathy: a potentially catastrophic complication of the percutaneous coronary interventions. *Int J Cardiol*; 134:431-433.
- Izzedine H, Launay-Vacher V, Baumelou A, Deray G. (2001):** An appraisal of antiretroviral drugs in hemodialysis. *Kidney Int*; 60:821-830.
- Izzedine H, Launay-Vacher V, Deray G. (2005):** Antiviral drug induced nephrotoxicity. *Am J Kidney Dis*; 45: 804–817.
- Jaber BI, Pereira JG, Bonventre JV, Balakrishnan VS. (2005):** Polymorphism of host response genes: Implications in the pathogenesis and treatment of acute renal failure. *Kid Internat*; 67:14-33.
- Jacoby GA, Matsell D, Sterner H, Kent KM, Munoz-Price LS. (2005):** The new β -lactamases. *New Eng J Med*; 352:380-391.
- Jayakumar M, Prabahar MR, Fernando EM, Manorajan R, Venkatraman R, Balaraman V. (2006):** Epidemiologic trend changes in acute renal failure- a tertiary center experience from South India. *Renal Failure*; 28:405-410.
- Jayasekara D, Aweeka FT, Rodriguez R, Kalayjian RC, Humphreys MH, Gambertoglio JG. (1999):** Antiviral therapy for HIV patients with renal insufficiency. *JAIDS*; 21: 384-395.
- Jeliffe R, Maire P. (2003):** Aminoglycoside dosages and nephrotoxicity. *Clin Pharmacokinet*; 42: 493–500.
- Jerkic M, Vojvodic S, Lopez-Novoa JM. (2001):** The mechanism of increased renal susceptibility to toxic substances in the elderly. Part I. The role of increased vasoconstriction. *Int Urol Nephrol*; 32: 539–547.

- Josephson MA, Chiu MY, Woodle ES, Thistlethwaite JR, Haas M. (1999):** Drug-induced acute interstitial nephritis in renal allografts: Histopathologic features and clinical course in six patients. *Am J Kidney Dis*; 34(3):540-8.
- John A (2006):** Atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Renal Data System, *USRDS 2006 Annual Data Report US*; 2:68-69.
- Juma FD, Rogers HJ, Trounce JR, et al. (1999):** Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. *Br J Clin Pharmacol*; 8:209-217.
- Kadkhodae M, Khastar H, Faghihi M, Ghaznavi R, Zahmatkesh M. (2005):** Effects of co supplementation of vitamins E and C on gentamicin-induced nephrotoxicity in rat." *Exp Physiol*"; 90:571–576.
- Kadkhodae M, Khastar H, Arab HA, Ghaznavi R, Zahmatkesh M, Mahdavi-Mazdeh M. (2007):** Antioxidant vitamins preserve superoxide dismutase activities in gentamicin-induced nephrotoxicity. *Transplantation Proceedings*; 39:864–865.
- Karahan I, Atessahin A, Yilmaz S, Ceribasi AO, Sakin F. (2005):** Protective effect of lycopene on gentamicin induced oxidative stress and nephrotoxicity in rats, *Toxicology*; 215:198–204.
- Katholi RE, Taylor GJ, McCann WP, Woods WT, Womack KA, McCay CD, Katholi CR, Moses HW, Mishkel GJ, Lucore CL, Holloway RM, Miller BP, Woodruff RC, Dove JT, Michel FL, Schneider JA. (1995):** Nephrotoxicity from contrast media: attenuation with theophylline. *Radiology*; 195:17-22.
- Katzberg RW (1997):** Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. *Radiology*; 204: 297-312.

- Khoury Z, Schlicht JR, Como J, Karschner JK, Shapiro AP, Mook WJ, Weber RJ. (1995):** The effect of prophylactic nifedipine on renal function in patients administered contrast media. *Pharmacotherapy*; 15:59-65.
- Kim R, Rotnitsky A, Sparrow D, Weiss S, Wager C and Hu H. (1996):** A longitudinal study of low-level lead exposure and impairment of renal function. The Normative Aging Study. *JAMA*; 275.
- Kini A, Sharma S, et al. (2001):** Managing the high-risk patients: Experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. *Rev Cardiovas Med*; 2:19-25.
- Kinsey GR, Gilbert R, Brian S, Cummings B, Caroline S, Beckett C, Geraldine SB. (2005):** Identification and distribution of endoplasmic reticulum iPLA2. *Biochem Biophys Acta*; 327:287.
- Khakurel S, Satyal PR, Agrawal RK, Chhetri PK, Hada R. (2005):** Acute renal failure in a tertiary care center in Nepal. *JNMA J Nepal Med Assoc*; 44: 32–35.
- Kleinberg M (2006):** What is the current and future status of conventional amphotericin B? *Int J Antimicrob Agents*;27(1):12-6.
- Koch JA, et al. (2000):** Prostaglandin E₁: a new agent for the prevention of renal dysfunction in high-risk patients caused by radiocontrast media? *Nephrol Dial Transplant*; 15:43.
- Kohda Y, Gemba M, et al. (2001):** Modulation by cyclic AMP and phorbol myristate acetate of cephaloridine-induced injury in rat renal cortical slices. *Jpn J Pharmacol*; 85(1): 54-59.
- Kohda Y, Gemba M, et al. (2002):** Enhancement of protein kinase C activity and chemiluminescence intensity in mitochondria isolated from the kidney cortex of rats treated with cephaloridine. *Biochem Pharmacol*; 64:543-549.
- Kohler C, Orrenius S, Zhivotovsky B. (2002):** Evaluation of caspase activity in apoptotic cells. *J Immunol Methods*; 265:97.

- Kohli HS, Bhaskaran MC, Muthukumar T, Thennarasu K, Sud K, Jha V, Gupta KL, Sakhuja V. (2000):** Treatment-related acute renal failure in the elderly: a hospital-based prospective study. *Nephrol Dial Transpl*; 15: 212-217.
- Krasuski RA, Beard BM, Geoghagan JD, Thompson CM, Guidera SA. (2003):** Optimal timing of hydration to erase contrast-associated nephropathy: The OTHER CAN study. *J Invasive Cardiol*; 15: 699–702.
- Kumar VK, Naidu MUR, Shifow A, Ratnakar KS. (2000):** Probucol protects against gentamicin-induced nephrotoxicity in rats. *Indian J Pharmacol*; 32: 108-13.
- Kurnik BRC, Allgren RL, Genter FC, Solomon RJ, Bates ER, and Weisberg LS. (1998):** Prospective study of atrial natriuretic peptide for the prevention of contrast-induced nephropathy. *Am J Kidney Dis*; 31:674-680.
- Kurz T, Terman A, Brunk UT. (2007):** Autophagy, ageing and apoptosis: the role of oxidative stress and lysosomal iron. *Arch Biochem Biophys*; 462:220–230.
- Lalezari JP, Henry K, O’Hearn M, et al. (2003):** Pentamidine, an HIV-1 fusion inhibitor, for drug resistant HIV infection in North and South America. *N Engl J Med*; 348:2175-2185.
- Lameire N, Van Biesen W, Vanholder R. (2006):** The changing epidemiology of acute renal failure. *Nat Clin Pract Nephrol*; 2: 364–377.
- Lancelot E, Idee JM, Couturier V, et al. (1999):** Influence of viscosity of iodixanol of medullary and cortical blood flow in the rat kidney: a potential cause of nephrotoxicity. *J Appl Toxicol*; 19:341-346.
- Lankiewicz S, Marc LC, Truc BN. (2000):** Activation of calpain I converts excitotoxic neuron death into a caspase-independent cell death. *J Biol Chem*; 275: 17064.
- Lee W, Kim RB. (2004):** Transporters and renal drug elimination. *Annu Rev Pharmacol Toxicol*; 44:137.

- Leffler PE, Jin T, Nordberg GF. (2000):** Differential calcium transport disturbances in renal membrane vesicles after cadmium-metallothionein injection in rats. *Toxicology*; 143: 227-234.
- Levin S, Thorlin T, Robinson KR, Nogi T, Mercola M. (1999):** The nomenclature of cell death: recommendations of an ahoy Committee of the Society of Toxicological Pathologists. *Toxicol Pathol*; 27:484.
- Liss P, et al. (2004):** Effect of furosemide ore mannitol before injection of a non-ionic contrast medium on intrarenal oxygen tension. *Adv Exp Med Biol*; 471:353.
- Litterst CL, Torres IJ, Guarino AM, et al. (1999):** Plasma levels and organ distribution of platinum in the rat, dog, and dog fish following intravenous administration of cis-DDP[II]. *J Clin Hemat Oncol*; 7: 169-78.
- Liu X, Rainey JJ, Harriman JF, Schnellmann RG. (2001):** Calpains mediate acute renal cell death: role of autolysis and translocation. *Am J Physiol Renal Physiol*; F281:F728.
- Liu X, Schnellmann RG. (2003):** Calpain mediates progressive plasma membrane permeability and proteolysis of cytoskeleton-associated paxillin, talin, and vinculin during renal cell death. *J Pharmacol Exp Ther*; 304:63.
- Madyoon H, Croushore L, Weaver D, Mathur V. (2001):** Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. *Cather Cardiovasc. Intervent*; 53;341-345.
- Maioli M, Toso A, Leoncini M. (2008):** Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. *J Am Coll Cardiol*; 52:599-604.
- Mancuso DJ, Jenkins CM, Gross RW, et al. (2000):** The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A. *Journal of Biological Chemistry*; 275: 9937.

- Manor SM, Guillory GS, Jain SP. (2004):** Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting. *Pharmacotherapy*; 24:664-667.
- Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, Trabatttoni D, Fabbiochi F, Montorsi P, Bartorelli AL. (2003):** The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. *N Engl J Med*; 349: 1333-1340.
- Marie-Paule ML, Paul MT. (1999):** Aminoglycosides: Nephrotoxicity. *Antimicrobial Agents and Chemotherapy. American Society for Microbiology*; 43(5):1003-1012.
- Mark AP (2009):** Renal Vulnerability to Drug Toxicity "Clinical Journal of American Society of Nephrology; 4: 1275-1283.
- Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D'Agati VD. (2001):** Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. *J Am Soc Nephrol*; 12:1164-1172.
- Markowitz GS, Perazella MA. (2005):** Drug induced renal failure: a focus on tubulointerstitial disease. *Clin Chim Acta*; 351:31-47.
- Marsden PA (2003):** Increased body lead burden-cause or consequence of chronic renal insufficiency?. *N Eng J Med*; 348: 345-347.
- Martinez-Salgado C, Rodríguez-Barbero A, Eleno N, López-Novoa JM. (2005):** Gentamicin induces Jun–AP1 expression and JNK activation in renal glomeruli and cultured mesangial cells. *Life Sci*; 77:2285-2298.
- Martinez-Salgado C, Lopez-Hernandez FJ, Lopez-Novoa JM. (2007):** Glomerular nephrotoxicity of aminoglycosides. *Toxicol Appl Pharmacol*. 223:86–98.
- Mavichak V, Wong NLM, Quamme GA, Magil AB, Sutton RAL, Dirks JH. (2001):** Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. *Kidney Int*; 28: 914-21.

- Megyesi J, Lucia Andrade L, Jose M, Vieira Jr, Robert L, Peter MP. (2001):** Positive effect of the induction of p21WAF1/CIP1 on the course of ischemic acute renal failure. *Kidney Int*; 60:2164.
- Mehran R, Aymong ED, Nikolsky E. (2004):** A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol*; 44:1393-1399.
- Mehta R, Pascual MT, Soroko S. Savage BR. (2004):** Himmelfarb J, Ikizler TA, Paganini EP, Chertow GM: Spectrum of acute renal failure in the intensive care unit: The PICARD experience. *Kid Internat*; 66:1613 1621.
- Merten GJ, Burgess WP, Gray LV. (2004):** Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. *JAMA*; 291:2328-2334.
- McCartney MM, et al. (1999):** Metformin and contrast media are a dangerous combination?. *Clin Radiol*; 54:29.
- McCormack JP (2000):** An emotional-based medicine approach to monitoring once- daily aminoglycosides. *Pharmacother*; 20(12): 1524-1527.
- McCullough PA, et al. (1997):** Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. *Am J Med*; 103:368.
- McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F. (2006):** Risk prediction of contrast-induced nephropathy. *Am J Cardiol*; 98:27K-36.
- McLarnon S, Holden D, Ward D, Jones M, Elliott A, Riccardi D. (2002):** Aminoglycoside antibiotics induce pH-sensitive activation of the calciumsensing receptor. *Biochem. Biophys. Res Commun*; 297:71–77.
- McLellan LI, Lewis AD, Hall DJ, Ansell JD, Wolf CR. (1995):** Uptake and distribution of N-acetyl-L-cystiene in mice. Tissue specific effects on glutathione concentrations. *Carcinogenesis*; 16:2099-2106.
- Meriel M, Hendrikus JM, van Kan Marcus J, Schultz EJ. (2008):** Systemic tobramycin concentrations during selective decontamination of the digestive

tract in intensive care unit patients on continuous venovenous hemofiltration. *Intensive Care Med*; 34:903–906.

Miller HI, et al. (2003): Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure. A randomized, parallel, double-blind clinical trial. *Am J Nephrol*; 23:91.

Miller JA, Anacta LA, Cattran DC. (1999): Impact of gender on the renal response to angiotensin II. *Kidney Int*; 55: 278-285.

Mingeot-Leclercq MP, Tulkens PM, et al. (1999): Aminoglycosides: nephrotoxicity, *Antimicrob Agents Chemotherap*; 43(5): 1003-1012.

Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. (2004): Neutrophil gelatinase associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. *Am J Nephrol*; 24:307–315.

Miyazaki T, Sagawa R, Honma T, Noguchi S, Harada T, Komatsuda A, Ohtani H, Wakui H, Sawada K, Otaka M, Watanabe S, Jikei M, Ogawa N, Hamada F, Itoh H. (2004): 73-kDa molecular chaperone HSP73 is a direct target of antibiotic gentamicin. *J Biol Chem*; 279(17): 17295-17300.

Mockel M, Radovic M, Kuhnle Y, Combe V, Waigand J, Schroder S, Dietz R , Frei U, Eckardt KU. (2008): Acute renal haemodynamic effects of radiocontrast media in patients undergoing left ventricular and coronary angiography. *Nephrol Dial Transplant*; 23(5): 1588-1594.

Moerstrup SK, Cui S, Vorum H, Bregengard C, Bjorn SE, Norris K, Gliemann J, Christensen EI. (1995): Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. *J Clin Investig*; 96:1404-1413.

Moffett BS, Rosenstein BJ, Mogayzel PJ. (2003): Ciprofloxacin-induced renal insufficiency in cystic fibrosis. *J Cyst Fibros*; 2(3):152-4.

Monica P, Gulie L. (2009): Renal risk evaluation in contrast media-induced nephropathy. *Therapeutics, Pharmacology and Clinical Toxicology*; 13: 104-106.

- Morales S, Camello PJ, Alcon S, Salido GM, Mawe G, Pozo MJ. (2004):** Coactivation of capacitative calcium entry and L-type calcium channels in guinea pig gallbladder. *Am J Physiol: Gastrointest Liver Physiol*; 286: 1090-1100.
- Morcos SK, Thomsen HS, Webb JA. (1999):** Contrast media- induced nephrotoxicity: a consensus report. *Eur Radiol*; 9:1602–13.
- Mori H, Kuroda Y, Imamura S, Toyoda A, Yoshida I, Kawakami M, et al. (2003):** Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole. *Internal medicine*; 42(8):665-9.
- Mosenkis A, Kirk D, Berns JS. (2006):** When chronic kidney disease becomes advanced, *Postgrad Med*; 119(1): 83-104.
- Mueller C, Buerkle G, Buettner HJ. (2002):** prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. *Arch Intern Med*; 162:329-336.
- Murakami H, Yayama K, Chao L, Chao J. (1998):** Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. *Kidney Int*; 53: 1305–1313.
- Murphy SW, Barrett BJ, Parfrey PS. (2000):** Contrast nephropathy. *J Am Soc Nephrol*; 1:177-182.
- Nagai J, Takano M. (2004):** Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. *Drug Metab. Pharmacokineti*; 19, 59–170.
- Nash K, Hafeez A, Hou S. (2002):** Hospital-acquired renal insufficiency. *American Journal of Kidney Disease*; 39:930-936.
- Nicolau DP, Freeman CD, Belliveau PP. (1995):** Experience with once-daily aminoglycoside program administered to 2184 adult patients. *Antimicrob Agents Chemother*; 39(3): 650-655.

- Nikolsky E, Mehran R. (2003):** Understanding the consequences of contrast-induced nephropathy. *Rev Cardiovasc Med*; 4(5): s10-s18.
- Nina I, Eran L, Stefan SP. (2000):** Pharmacokinetics of Gentamicin C1, C1a, and C2 in Beagles after a Single Intravenous Dose. *Antimicrobial Agents and Chemotherapy*; 44: 1443–1447.
- Nobilis A, Kocsis I, Toth-Heyn P, Treszl A, Schuler A, Tulassay T, Vasarhelyi B. (2001):** Variance of ACE and AT1 receptor gene does not influence the risk of neonatal acute renal failure. *Pediatr Nephrol*; 16(12): 1063-1066.
- Nolan CR, Anderson RJ, et al. (1998):** Hospital-acquired acute renal failure. *JASN*; 9: 710-718.
- Nordberg M, Nordberg G. (2000):** Toxicological aspects of metallothionein. *Cellul Mol Biol*; 46: 451-463.
- Nowak G, Price PM, Schnellmann RG. (2003):** Lack of a functional p21WAF1/CIP1 gene accelerates caspase-independent apoptosis induced by cisplatin in renal cells. *Am J Physiol Renal Physiol*; 285:F440.
- Nowak G, Bakajsova D, Clifton GL. (2004):** Protein kinase C- ϵ modulates mitochondrial function and active Na⁺ transport after oxidant injury in renal cells. *Am J Physiol Renal Physiol*; F286:F307.
- Obialo CI, Okonofua EC, Tayade AS, Riley LJ. (2000):** Epidemiology of de novo acute renal failure in hospitalized African Americans. *Arch Intern Med*; 160:1309-1313.
- Obialo CI, Crowell AK, Okonofua EC, et al. (2002):** Acute renal failure mortality in hospitalized African Americans: age and gender considerations. *J Natl Med Assoc*; 94(3): 127-134.
- Ocal H, Yuksel M, Ayar A. (2004):** Effects of gentamicin sulfate on the contractility of myometrium isolated from non-pregnant cows. *Anim. Reprod. Sci*; 84:269–277.

- Oldroyd S, Slee SJ, Haylor J. (2000):** Effects of adenosine receptor antagonists on the responses to contrast media in the isolated rat kidney. *Clin Sci*; 98:303-311.
- Owens RC, Nolin TD. et al. (2006):** Antimicrobial-associated QT interval prolongation: points of interest. *Clin Infect Dis*; 43(12):1603-11.
- Ozcan EE, Guneri S, Akdeniz B. (2007):** Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy: a comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures: a single-center prospective controlled trial. *Am Heart J*; 154:539-544.
- Page MG (2000):** B-Lactamase inhibitors. *Drug Resist Updat* 2000; 3(2): 109-125.
- Park KM, Chen A, Bonventre JV. (2001):** Prevention of kidney ischemia/reperfusion-induced functional injury and JNK, p38, and MAPK kinase activation by remote ischemic pretreatment. *J Biol Chem*; 276:11870.
- Pedraza-Chaverri J, Gonzalez-Orozco AE, Maldonado PD. (2003):** Diallyl disulfide ameliorates gentamicin-induced oxidative stress and nephropathy in rats. *Eur J Pharmacol*; 473:71-74.
- Perazella MA, Tray K, et al. (2001):** Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional non-steroidal anti-inflammatory drugs. *Am J Med*; 111:64-7.
- Perazella MA (2005):** Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. *Am. J. Med. Sci.* 325, 349–362.
- Perneger TV, Whelton PK, Puddey IB, Klag MJ. (1999):** Risk of end-stage renal disease associated with alcohol consumption. *Am J Epidemiol*; 150: 1275-1281.
- Pflueger A, Larson, TS, Nath KA, King BF, Gross JM, Knox, FG. (2000):** Role of adenosine in contrast media induced acute renal failure in diabetes mellitus. *Mayo Clin Proc*; 75:1275-83.

- Price PM, Safirstein RL, Megyesi J. (2004):** Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. *Am J Physiol Renal Physiol*; 286:F378.
- Priuska EM, Schacht J. (1997):** Mechanism and prevention of aminoglycoside ototoxicity: outer hair cells as targets and tools. *Ear Nose Throat J*; 76:164-171.
- Radovic M, Tomovic M, Simic-Ogrizovic S, Stosovic M, Lezaic V, Ostric V, Djukanovic L. (2004):** An improvement in the outcome of acute renal failure. *Renal Failure*; 26:647-653.
- Ravieh D, Kopyt M, Hite Y, Rudensky B, Sonnenblick M, and Yinnon AM. (2002):** Risk factors for nephrotoxicity in elderly patients receiving once daily aminoglycoside. *Q J Med*; 95:291-297.
- Ravnskov U, Ravnskov U, et al. (1999):** Glomerular, tubular and interstitial nephritis associated with non-steroidal anti-inflammatory drugs. Evidence of a common mechanism. *British Journal of Clinical Pharmacology*; 47: 203-210.
- Rihal CS, Textor SC, Grill DE. (2002):** incidence and prognostic importance of acute renal failure after percutaneous coronary intervention . *circulation*; 105:2259-2264.
- Rivas-Cabañero L, Rodríguez-López AM, Martínez-Salgado C, Saura M, Lamas S, López-Novoa JM. (1997):** Gentamicin treatment increases mesangial cell nitric oxide production. *Exp. Nephrol*; 5:23–30.
- Rodríguez-Barbero A, López-Novoa JM, Arévalo M. (1997):** Involvement of platelet-activating factor in gentamicin nephrotoxicity in rats. *Exp. Nephrol*; 5:47–54.
- Rodriguez-Puyol D (1998):** The aging kidney. *Kidney Int*; 54: 2247-2265.
- Ronco C, Zanella M, Brendolan A, Milan M, Canato G, Zamperetti N, Bellomo R. (2001):** Management of severe acute renal failure in critically ill patients:

an international survey in 345 centres. *Nephrol Dial Transplant*; 16(2): 230-237.

Rougier F, Claude D, Maurin M, Sedoglavic A, Ducher M, Corvaisier S, Jelliffe R and Maire P. (2003): Aminoglycoside Nephrotoxicity: Modeling, simulation and control. *Antimicrobial Agents Chemother*; 47:1010-1016.

Rui-Mei L, Kara AU, Sinniah R. (1998): In situ analysis of adhesion molecule expression in kidneys infected with murine malaria. *J Pathol*; 185:219.

Sabra R, Zeinoun N, Sharaf LH, et al. (2001): Role of humoral mediators in, and influence of a liposomal formulation on, acute amphotericin B nephrotoxicity. *Pharmacol Toxicol*; 88:168-75.

Safirstein RL (1999): Anticancer drugs. In *Clinical Nephrotoxins*, **Debroe ME, Porter GA, Bennett WM, Verpoten GA.** Kluwer Academic Publ. Dordrecht; 261-271.

sandborgh-Englund G, Nygren, AT, Ekstrand J, Elinder CG. (1996): No evidence of renal toxicity from amalgam fillings. *Am J Physiol*; 271: R941-R945.

Sandler DP, Smith JC, Weinberg CR, Buckalew VM Jr, Dennis VW, Blythe WB, Burgess WP. (1998): Analgesic use and chronic renal disease. *N Engl J Med*; 320(19): 1238-1243.

Sandoval RM, Molitoris BA, et al. (2004): Gentamicin traffics retrograde through the secretory pathway and is released in the cytosol via the endoplasmic reticulum. *Am J Physiol Renal Physiol*; 286:F617-624.

Sandoval RM, Reilly JP, Running W, Campos SB, Santos JR, Phillips CL, Molitoris BA. (2006): A non-nephrotoxic gentamicin congener that retains antimicrobial efficacy, *J Am Soc Nephrol*; 17: 2697-2705.

Segasothy M, Chin GL, Sia KK, et al. (1995): Chronic nephrotoxicity of anti-inflammatory drugs used in the treatment of arthritis. *British Journal of Rheumatology*; 34: 162-165.

- Scanlon PJ, Faxon DP, Audet AM, Carabello, B, Dehmer GJ, Eagle KA, Legako RD, Leon DF, Murray JD, Nissen SE, Pepine CJ, Watson RM, Ritchie JL, Gibbons RJ, Cheitlin MD, Gardner TJ, Garson A, Russell RO, Ryan TJ, Smith SC. (2003):** ACC/AHA guidelines for coronary angiography: a report of the American College of Cardiology/American Heart Association Task force on Practice Guidelines (Committee on Coronary Angiography). *J Am Coll Cardiol*;33:1756-824.
- Schaub TP, Kartenbeck J, Konig J, Spring H, Dorsam J, Sthaeler G, Storkel S, Thon WF, Keppler D. (1999):** Expression of the MRP2 gene encoded conjugate export pump in human kidney proximal tubule and in renal carcinoma. *J Am Soc Nephrol*; 10(6):1159-1169.
- Schetz M, Dasta J, Goldstein S, Golper T. (2005):** Drug-induced acute kidney injury. *Curr Opin Crit Care*; 11: 555–565.
- Schilsky RL, Barlock A, Ozols RF. (1999):** Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. *Cancer Treat Reports*; 66: 1767-1769.
- Schmidt C, Pang D, Nykamp D, Knowlton G, Jia H. (2007):** N-acetylcysteine and sodium bicarbonate versus N-acetylcysteine and standard hydration for the prevention of radiocontrast-induced nephropathy following coronary angiography. *Ann Pharmacother*; 41: 46–50.
- Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. (2006):** Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. *Am J Epidemiol*; 164:881-889.
- Schuler U, Ehninger G, Wagner T. (2000):** Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. *Cancer Chemother Pharmacol*; 20:248-252.

- Schwarz A, Krause PH, Kunzendorf U, Keller F, Distler A. (2000):** The outcome of acute interstitial nephritis: Risk factors for the transition from acute to chronic interstitial nephritis. *Clin Nephrol*; 54:179-190.
- Schwerdt G, Drumm K, Gekle M, Peraica M, Domijan AM, Matasin M, Lucic A, Radic B, Delas F, Horvat M. (2004):** Inhibition of mitochondria and extracellular acidification enhance achratoxin A-induced apoptosis in renal collecting duct-derived MDCK-C7 cells. *Cell Physiol Biochem*;14:47.
- Seeliger E, Flemming B, Wronski T, Ladwig M, Arakelyan K, Godes M, Mockel M, Persson PB. (2007):** Viscosity of contrast media perturbs renal hemodynamics. *J Am Soc Nephrol*; 18: 2912-2920.
- Servais H, Jossin Y, Van Bambeke F, Tulkens PM, Mingeot-Leclercq MP. (2006):** Gentamicin causes apoptosis at low concentrations in renal LLC-PK1 cells subjected to electroporation. *Antimicrob Agents Chemotherap*; 50(4): 1213-21.
- Sesso R, Roque A, Vicioso B, Stella S. (2004):** Prognosis of AKI in Hospitalized elderly patients. *Am J Kid Dis*; 44:410-419.
- Simon DI, Brosius FC, Rothstein DM. (1995):** Sulfadiazine crystalluria revisited. The treatment of *Toxoplasma* encephalitis in patients with acquired immunodeficiency syndrome. *Archives of internal medicine*; 150(11):2379-84.
- Singh NP, Ganguli A, Prakash A. (2003):** Drug-induced kidney diseases. *JAPI*;51: 970–979.
- Shitara Y, Sato H, Sugiyama Y. (2005):** Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. *Annu Rev Pharmacol. Toxicol*; 45:689-723.
- Sketch MH (2001):** Prevention of contrast media-induced renal dysfunction with prostaglandin E₁: a randomized, double-blind, placebo-controlled study. *Am J Ther*; 8:155.

- Stacul F, Cova M, et al. (2003):** Contrast media-induced nephropathy: risk assessment and reduction. *Contrast media induced nephrotoxicity : problems in clinical practice*; 105:36-41.
- Starr R. (1998):** Treatment of acute renal failure *Kid Internat.* 1998;54:1817-1831.
- Stevens MA, McCullough PA, Tobin KJ, Speck JP, Westveer DC, Timmes GC, O'Neill WW. (1999):** A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy. *J Am Coll Cardiol*; 33:403-411.
- Stone CW, Peter A, James A, Norman E, Alan CHu, and Gary L. (2003):** Fenoldopam mesylate for the prevention of contrast-induced nephropathy. A randomized controlled trial. *JAMA*; 290:2284.
- Sundin DP, Sandoval R, Molitoris BA. (2001):** Gentamicin inhibits renal protein and phospholipid metabolism in rats: implications involving intracellular trafficking. *J Am Soc Nephrol*; 12(1):114.
- Sweet DH, Bush KT, Nigam SK, et al. (2001):** The organic anion transporter family: from physiology to ontogeny and the clinic. *Am J Physiol Renal Physiol*; 281:F197.
- Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. (1997):** Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. *Hyperten*; 29:274-279.
- Tamura M, Tanaka H, Yashiro A, Osajima A, Okazaki M, Kudo H, Doi Y, Fujimoto S, Higashi K, Nakashima Y, Hirano H. (2000):** Expression of profilin, an actin-binding protein, in experimental glomerulonephritis and its upregulation by basic fibroblast growth factor in cultured mesangial cells. *J. Am. Soc. Nephrol*; 11:423–433.
- Taylor AJ, Hotchkiss D, Morse RW, McCabe J. (1998):** preparation for angiography in renal dysfunction. A randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild to moderate renal dysfunction. *Chest*; 114:1570-1574.

- Terada T, Saito H, Mukai M. (2002):** Inui K-I. Recognition of β -lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2 in LLC-Pk1 cells. *Am J Physiol Renal Physiol*; 273(42): F706-F711.
- Tikoo K, Lau SS, Monks TJ. (2001):** Histone H3 phosphorylation is coupled to poly-(ADP-ribosylation) during reactive oxygen species-induced cell death in renal proximal tubular epithelial cells. *Mol Pharmacol*; 60:394.
- Traynor J, Mactier R, Geddes CC, Fox JG. (2006):** How to measure renal function in clinical practice. *BMJ*; 333:733-737.
- Trivedi HS, Moore H, Nasr S. (2003):** A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. *Nephron Clin Pract*; 93:c29-c34.
- Tune BM. (1993):** The nephrotoxicity of cephalosporin antibiotics. Structure-activity relationship. *Commun Toxicol*; 1: 145-157.
- Urakami Y (2003):** Molecular diversity of organic cation transporter mediating renal excretion of drugs. *WILEY*; 34:957.
- Vachvanichsanong P, Dissaneewate P, Lim A, McNeil E. (2006):** Childhood acute renal failure: 22-Year experience in a university hospital in southern Thailand. *Pediatrics*. 118: e786–e791.
- Vackulenko SB, Moashery S. (2003):** Versatility of aminoglycosides and prospects for their future. *Clinical Microbiology Reviews*; 16: 430-50.
- Van Aubel MH, Masereeuw R, Russel FGM. (2000):** Molecular pharmacology of renal organic anion transporters. *Am J Physiol Renal Physiol*; 279(2): F216-F232.
- Varlam DE, Siddiq MM, Parton LA, Russmann H, et al. (2001):** Apoptosis contributes to amphotericin B-induced nephrotoxicity. *Antimicrob Agents Chemother*;45:679-85.
- Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougnot B, Girard PM, Ronco P, Rossert J. (2002):** Fanconi syndrome and renal failure induced by tenofovir: a first case report. *Am J Kidney Dis*; 40:1331-1333.

- Wang A, Holcslaw T, Bashore TM. (2000):** Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. *Kidney Int*; 57:1675-1680.
- Waybill MM, Waybill PN. (2001):** Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. *J Vasc Interv Radiol*; 12:3–9.
- Wang EJ, Snyder RD, Fielden MR. (2008):** Validation of putative genomic biomarkers of nephrotoxicity in rats. *Toxicology*; 246:91–100.
- Wang J, Mullins CD, Mamdani M, Rublee DA, Shaya FT (2007):** New diagnosis of hypertension among celecoxib and nonselective NSAID users: A population-based cohort study. *Ann Pharmacother*; 41:937-43.
- Weisbord SD, Bruns FJ, Saul MI, Palevsk, PM. (2004):** Provider use of preventive strategies for radiocontrast nephropathy in high-risk patients. *Nephron Clin Pract* 96:c56-62.
- Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD. (1992):** Acute renal failure *Kidney Dis*; 20: 281-285.
- Whelton A, Whelton A, et al. (2000):** Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. *American Journal of Medicine*; 106: 13S-24S.
- White WB, Kent J, Taylor A, et al. (2002):** Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. *Hypertension*; 39: 929-934.
- Winston JA, Safirstein R, et al. (2001):** Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. *Am J Physiol*; 249: F490-496.
- Wright SH, Dantzler WH, et al. (2004):** Molecular and cellular physiology of renal organic cation and anion transport. *Physiol Rev*; 84:987.
- Wyatt CM, Arons RR, Klotman PE, Klotman ME. (2006):** Acute renal failure in hospitalized patients with HIV: Risk factors and impact on in-hospital mortality. *AIDS*; 20: 561–565.

- Xue JL, Daniels F, Starr RA, Kimmel PL, Eggers PW, Molitoris BA, Himmelfarb J, Collins AJ. (2006):** Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. *J Am Soc Nephrol*; 17:1135-42.
- Yano Y, Hiraoka A, Oguma T. (1998):** Enhancement of tobramycin binding to rat renal brush border membrane by vancomycin, *J Pharmacol Exp Ther*; 274: 695-99.
- Yu CC, Lin JL, Lin-Tan DT. (2004):** Environmental exposure to lead and progression of chronic renal diseases: A four-year prospective longitudinal study. *J Am Soc Nephrol*; 15: 1016–1022.
- Zager RA, Jonson ACM, Hanson SY. (2003):** Radiographic contrast media-induced tubular injury. Evaluation of oxidants stress and plasma membrane integrity. *Kidney Int*; 64:128-139.
- Zager RA, Johnson AC, Hanson SY, Lund S. (2005):** Ischemic proximal tubular injury primes mice to endotoxin-induced TNF- α generation and systemic release. *Am J Physiol*; 289: 289-297.
- Zahar JR, Rioux C, Girou E, Hulin A, Sauve C, Bernier-Combes A, Brun-Buisson C, Lesprit P. (2006):** Inappropriate prescribing of aminoglycosides: risk factors and impact an antibiotic control team. *J Antimicrob Chemother*; 58:651-656.

الأدوية المسببة للاعتلال الكلوي

رسالة مقدمة للحصول علي درجة الماجستير في أمراض الباطنة العامة

من الطبيب

إبراهيم رضا القاضي

بكالوريوس الطب و الجراحة ، جامعة الإسكندرية

تحت إشراف

أ.د / نبيل السيد عطية خطاب

أستاذ الباطنة العامة

كلية الطب – جامعة بنها

أ.د / توحيد محمد موافي

أستاذ الباطنة العامة

كلية الطب – جامعة بنها

د / علي السيد علي

مدرس الباطنة العامة

كلية الطب – جامعة بنها

كلية الطب

جامعة بنها

٢٠١١